Session Information
Session Type: Abstract Submissions (ACR)
Background/Purpose: Neutrophils and neutrophil death (“netosis”) are now understood to play a role in the pathogenesis of SLE. A neutrophil gene signature exists in SLE, although its association with the clinical phenotype is unknown.
Methods: A total of 292 SLE patients were included in the analysis. Among these patients, 91.1% were female; 58.9% were Caucasian, 33.9% were African-American, and 7.2% were other ethnicities. Mean age (standard deviation) at baseline was 46.0 (±11.9) years. Neutrophil gene expression was high (>6) in 31.9% (N=93), medium (5-6) in 31.5% (N=92), and low (<5) in 36.6% (N=107) of patients.
Results:
The neutrophil gene signature was more common in Caucasians (p=0.045). The neutrophil gene signature is strongly associated with same day disease activity, serologies (anti-dsDNA and low complements), and need for prednisone. It is also strongly associated with poor outcomes (myocardial infarction, deep venous thrombosis, diabetes, malignancy).
Table 1. Association between Same-day Visit Disease Activity and Neutrophil Gene Signature
Variable |
Low Neutrophil (<5) (%, N=107) |
Med Neutrophil (5-6) (%, N=92) |
High Neutrophil (>6) (%, N=93) |
Adjusted P-value for Ethnicity |
Ethnicity African-American Caucasian Other |
36.5 57.9 5.6 |
42.4 52.2 5.4 |
22.6 66.7 10.8 |
0.045* |
Physician’s global assessment >1 |
11.2 |
16.3 |
30.1 |
0.003 |
SELENA SLEDAI ≥2 |
47.7 |
60.9 |
65.6 |
0.012 |
Age at visit (years) ≤30 >30 |
13.1 86.9 |
9.8 90.2 |
12.9 87.1 |
0.75 |
Use of Prednisone |
25.2 |
32.6 |
49.5 |
0.0007 |
Use of Plaquenil |
77.6 |
88.0 |
71.0 |
0.016 |
Use of Aspirin |
30.8 |
41.3 |
51.6 |
0.011 |
Anti-dsDNA ≥10 |
10.3 |
26.1 |
31.2 |
0.0005 |
Lupus Anticoagulant |
10.3 |
12.0 |
23.7 |
0.023 |
C3 <79 mg/dl |
8.4 |
8.7 |
20.4 |
0.031 |
C4 <12 mg/dl |
5.6 |
9.8 |
18.3 |
0.034 |
ESR >20 |
40.2 |
53.4 |
61.5 |
0.0018 |
* Unadjusted p-value.
Table 2. Association between SLICC/ACR Damage Index and Neutrophil Gene Expression in SLE
Variable |
Low Neutrophil (<5) (%, N=107) |
Med Neutrophil (5-6) (%, N=92) |
High Neutrophil (>6) (%, N=93) |
Adjusted P-value for Ethnicity |
Myocardial Infarction |
0.0 |
6.5 |
5.4 |
0.0056 |
Deep Venous Thrombosis |
1.9 |
0.0 |
6.5 |
0.016 |
Diabetes |
4.7 |
6.5 |
14.1 |
0.024 |
Malignancy |
2.8 |
12.1 |
15.2 |
0.0043 |
Conclusion: This is the first gene signature to be associated with myocardial infarction, deep venous thrombosis and malignancy. Targeting the neutrophil gene signature appears to be promising for disease activity. Given that atherosclerosis disease is the major cause of death in late SLE, this gene signature may be the “missing link” in understanding how SLE accelerates atherosclerosis. A limitation of the technique is that the neutrophil gene signature will go up when there is lymphopenia.
Disclosure:
M. Petri,
HGS,
5,
GlaxoSmithKline,
5,
Medimmune,
5,
UCB,
5,
Anthera,
5,
Pfizer Inc,
5,
TEVA,
5;
H. Fang,
None;
J. Bienkowska,
Biogen Idec,
3;
N. Allaire,
Biogen Idec,
3;
J. Browning,
Biogen Idec,
3;
S. Kalled,
Biogen Idec,
3.
« Back to 2012 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-between-neutrophil-gene-signature-and-disease-characteristics-in-systemic-lupus-erythematosus-patients/